Quick Answer
LISATA THERAPEUTICS, INC. reported Cash and Equivalents of $15.96 million for fiscal year 2025.
LISATA THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $15.96M | -1.6% |
| 2024 | $16.21M | -28.3% |
| 2023 | $22.59M | -29.7% |
| 2022 | $32.15M | +30.5% |
| 2021 | $24.65M | +49.3% |
| 2020 | $16.51M | +17.7% |
| 2019 | $14.03M | +36.2% |
| 2018 | $10.30M | -64.7% |
| 2017 | $29.16M | +312.1% |
| 2016 | $7.08M | -65.2% |
| 2015 | $20.32M | +6.0% |
| 2014 | $19.17M | -58.4% |
| 2013 | $46.13M | +235.8% |
| 2012 | $13.74M | +11.7% |
| 2012 | $12.30M | +212.6% |
| 2011 | $3.94M | -74.8% |
| 2010 | $15.61M | +118.1% |
| 2009 | $7.16M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.00M | -2.6% | +12.8% |
| June 30, 2025 | $16.84M | -40.5% | -16.7% |
| March 31, 2025 | $20.22M | -7.3% | +24.7% |
| December 31, 2024 | $16.21M | -28.3% | -16.9% |
| September 30, 2024 | $19.51M | -39.8% | -31.0% |
| June 30, 2024 | $28.29M | +19.4% | +29.8% |
| March 31, 2024 | $21.80M | -22.6% | -3.5% |
| December 31, 2023 | $22.59M | -29.7% | -30.3% |
- LISATA THERAPEUTICS, INC. showed a decrease of -1.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, LISATA THERAPEUTICS, INC.’s cash and equivalents has grown by 122.9% (from $7.16 million to $15.96 million).
- The most recent figure is from LISATA THERAPEUTICS, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: